PARP16 is a druggable regulator of ribosome MARylation and protein homeostasis in ovarian cancer cells
Sridevi Challa, Morgan Dasovich, Jonathan C Abshier, Komal Pekhale, Lu Yang, Cristel V Camacho, W Lee Kraus · 2026
Read PARP16 is a druggable regulator of ribosome MARylation and protein homeostasis in ovarian cancer cells by Sridevi Challa, Morgan Dasovich, Jonathan C Abshier, Komal Pekhale, Lu Yang, Cristel V Camacho, W Lee Kraus (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13671029.txt.
Description
Sridevi Challa and co-authors validate a drug target in ovarian cancer: an enzyme that tags ribosomes and keeps the cell's protein production balanced, in a 2026 study. The enzyme, PARP16, attaches a small chemical mark to ribosomal proteins using the cell's NAD+ supply. Removing it genetically disrupts the marking and slows tumor growth. The team tested a selective blocker, DB008, to see whether a drug could do the same.
The blocker stopped the enzyme's self-marking in the test tube, engaged it inside cancer cells, and cut ribosome marking there. Treated cells made protein faster but sloppily, piling up aggregates, and their growth and colony formation fell. Cells with the gene deleted ignored the drug entirely, and cells carrying a drug-resistant enzyme version were likewise unaffected, proving the effect is on-target. In mice, the drug significantly slowed implanted tumors. The authors call PARP16 a druggable regulator worth developing.
Catalog record
| CREATOR | Sridevi Challa, Morgan Dasovich, Jonathan C Abshier, Komal Pekhale, Lu Yang, Cristel V Camacho, W Lee Kraus |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 63 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |